Neurotrack competitors
Neurotrack's competitors include Transformative, NeuraLace Medical, EXACT Sciences and bioMerieux
Add company...
You can compare up to 12 companies. Please remove a company to add a new one
| Save ComparisonClear all |  Neurotrack Neurotrack's technology can predict the onset of Alzheimer's disease three to six years before symptoms occur. |  Transformative Transformative provides patent-pending algorithm to predict the onset of sudden cardiac arrest, allowing for advance warning, and preparation for intervention. |  NeuraLace Medical NeuraLace Medical has developed a proprietary neuromodulation platform for direct and selective stimulation of sensory nerve fibers to manage neuropathic pain. |  EXACT Sciences Exact Sciences is the developer and manufacturer of Cologuard, a non-invasive screening test for the early detection of colorectal cancer. |  bioMerieux bioMérieux provides diagnostic solutions which determine the source of disease and contamination to improve patient health and ensure consumer safety. |
Founding Date | Founding Date 2012 | Founding Date 2016 | Founding Date 2016 | Founding Date 1995 | Founding Date 1963 |
Type | Type Private | Type Private | Type Private | Type Public | Type Public |
Tags | |||||
Locations | Locations Redwood City, US HQ | Locations London, GB HQ | Locations San Diego, US HQ | Locations Madison, US HQ | Locations Marcy-l'Étoile, FR HQ |
Employees | Employees 249% increase | Employees 7 | Employees 8 | Employees 736 | Employees 9,8065% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 6 b | Valuation ($) 9.3 b |
Facebook likes | Facebook likes 3.4 k | Facebook likes N/A | Facebook likes N/A | Facebook likes 5.4 k | Facebook likes 8.5 k |
Twitter followers | Twitter followers 1.3 k | Twitter followers N/A | Twitter followers 22 | Twitter followers 2 k | Twitter followers 4.8 k |
Financial ⚠ | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $99.4m (FY, 2016) | Revenue (est.) €2.1b (FY, 2016) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $45.2m (FY, 2016) | Cost of goods €1b (FY, 2016) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit $54.2m (FY, 2016) | Gross profit €1.1b (FY, 2016) |
Net income | Net income N/A | Net income N/A | Net income N/A | Net income ($167.2m) (FY, 2016) | Net income €179.2m (FY, 2016) |
Funding | |||||
Latest funding round | Latest funding round $ 13.7m (5 months ago) | Latest funding round $ 669.6k (11 months ago) | Latest funding round $ 2m (over 1 year ago) | Latest funding round N/A | Latest funding round N/A |
Total funding raised | Total funding raised $ 26.1m | Total funding raised $ 669.6k | Total funding raised $ 2m | Total funding raised $ 8.2m | Total funding raised N/A |
For sources of this data, please see the company profileDownload Excel
View company profiles
Transformative
HQ
London, GB
Employees
7
Transformative provides patent-pending algorithm to predict the onset of sudden cardiac arrest, allowing for advance warning, and preparation for intervention.
View companyNeuraLace Medical
HQ
San Diego, US
Employees
8
NeuraLace Medical has developed a proprietary neuromodulation platform for direct and selective stimulation of sensory nerve fibers to manage neuropathic pain.
View companyEXACT Sciences
HQ
Madison, US
Employees
736
Exact Sciences is the developer and manufacturer of Cologuard, a non-invasive screening test for the early detection of colorectal cancer.
View companybioMerieux
HQ
Marcy-l'Étoile, FR
Employees
9,806↑ 5% increase
bioMérieux provides diagnostic solutions which determine the source of disease and contamination to improve patient health and ensure consumer safety.
View company